Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer

This study has been completed.
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT00142415
First received: August 31, 2005
Last updated: December 30, 2013
Last verified: December 2013

August 31, 2005
December 30, 2013
February 2005
March 2010   (final data collection date for primary outcome measure)
  • To determine the safety of increasing doses of 177Lu-DOTA-cG250 in patients with advanced renal cancer to establish the MTD [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • To determine the targeting and dosimetry of 177Lu-DOTA-cG250 in patients with advanced renal cancer, using 111In-DOTA-cG250 as a surrogate. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • 1)To determine the safety of increasing doses of 177Lu-DOTA-cG250 in patients with advanced renal cancer to establish the MTD
  • 2)To determine the targeting and dosimetry of 177Lu-DOTA-cG250 in patients with advanced renal cancer, using 111In-DOTA-cG250 as a surrogate.
Complete list of historical versions of study NCT00142415 on ClinicalTrials.gov Archive Site
Tumor response using RECIST criteria [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
1)Tumor response using RECIST criteria
Not Provided
Not Provided
 
Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer
Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 in Patients With Advanced Renal Cancer

The purpose of this study is to determine whether 177Lutetium-DOTA-cG250 is effective for treatment of patients with advanced renal cell carcinoma

This is a Phase I/II dose escalation study using 177Lu-DOTA-cG250 for treatment of patients with advanced renal cell carcinoma. The trial requires a minimum of 6 patients and a maximum of 18 patients. The initial group of patients will be treated with 30 mCi/m2 of Lu-177. Subsequent treatments will be in 10 mCi/m2 increments. At least three patients per dose level will be followed for up to 12 weeks with imaging, biochemical and hematologic tests to determine the safety of 177Lu-DOTA-cG250. CT scans will be carried out at baseline and after 12 weeks (or after recovery from toxicity), for response assessment.

Patients will initially receive 5 mCi/10 mg 111Indium-DOTA-cG250 antibody (an imaging dose preceeding Lu-177-cG250 treatment). Whole body and blood measurements of radioactivity will be obtained on at least three occasions for one week to determine targeting and dosimetry. Only if at least one known and evaluable metastatic lesion is visualized with In-111-cG250, therapeutic 177Lu-DOTA-cG250 will be administered the following week. In the absence of disease progression and after recovery from toxicity, patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments. Only patients who have normal pharmacokinetics on the preceding diagnostic In-111-cG250 study (indicative of HACA negativity) are eligible for retreatment.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Renal Cell Carcinoma
  • Drug: 111-In-DOTA-cG250
    At day 1, every patient received the cG250 at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of 111-Indium (111-In).
    Other Names:
    • cG250
    • DOTA-cG250
    • cG250-In111
  • Drug: 177-Lu-DOTA-cG250
    At day 8, every patient received the cG250 at a dose of 10 mg coupled to DOTA and labeled with a dose of 177-Lutetium (177-Lu) that started at 10 mCi by square meter for the patients of the 1st cohort.
    Other Names:
    • cG250
    • DOTA-cG250
    • cG200-Lu177
  • Experimental: Cohort 1, 30 mCi/m2 177-Lu-DOTA-cG250
    Patients in the first arm received 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
  • Experimental: Cohort 2, 40 mCi/m2 177-Lu-DOTA-cG250
    Patients in the second arm received 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
  • Experimental: Cohort 3, 50 mCi/m2 177-Lu-DOTA-cG250
    Patients in the third arm received 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
  • Experimental: Cohort 4, 60 mCi/m2 177-Lu-DOTA-cG250
    Patients in the fourth arm received 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
  • Experimental: Cohort 5, 70 mCi/m2 177-Lu-DOTA-cG250
    Patients in the fifth arm received 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
  • Experimental: Cohort 6, 65 mCi/m2 177-Lu-DOTA-cG250
    Patients in the sixth arm received 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m2 of 177-Lu-DOTA-cG250, once.
    Interventions:
    • Drug: 111-In-DOTA-cG250
    • Drug: 177-Lu-DOTA-cG250
Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
27
July 2013
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with proven advanced and progressive renal cell carcinoma of the clear cell type
  2. At least one evaluable lesion less than 5 cm
  3. Performance status: Karnofsky > or equal 70 %
  4. Laboratory values obtained less than 14 days prior to registration:

    • White blood cells (WBC) > or equal 3.5 x 109/l
    • Platelet count > or equal 100 x 109/l
    • Hemoglobin > or equal 6 mmol/l
    • Total bilirubin < or equal 2 x upper limit of normal (ULN)
    • ASAT, ALAT < or equal 3 x ULN (< 5 x ULN if liver metastases present)
    • Serum creatinine < or equal 2 x ULN
  5. Negative pregnancy test for women of childbearing potential (urine or serum)
  6. Age over 18 years
  7. Ability to provide written informed consent

Exclusion Criteria:

  1. Known metastases to the brain
  2. Untreated hypercalcemia
  3. Metastatic disease limited to the bone
  4. Pre-exposure to murine/chimeric antibody therapy
  5. Chemotherapy, external beam radiation or immunotherapy within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed, when unirradiated, evaluable lesions elsewhere are present.
  6. Cardiac disease with New York Heart Association classification of III or IV
  7. Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception
  8. Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgement of the investigator will significantly affect patients' clinical status
  9. Life expectancy shorter than 6 months.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00142415
LUD2003-006
No
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Radboud University
Principal Investigator: W.J.G. Oyen, MD, PhD Department of Nuclear Medicine, University Medical Center Nijmegen
Principal Investigator: P.F.A. Mulders, MD, PhD Department of Urology, University Medical Center Nijmegen
Ludwig Institute for Cancer Research
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP